Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
September 13, 2023
The Commitment to Development Index (CDI) ranks 40 of the world’s most powerful countries on policies that affect more than five billion people living in poorer nations. The focus of the index is on development “spillovers,” or policies that affect the development prospects of countries beyond one’s...
Blog Post
September 12, 2023
I utterly didn’t foresee the revolution in mobile internet services, and the incredibly innovative ways that it would be used. Back in 2002, 11 percent of the world’s population were internet users. Today, it is 63 percent—the considerable majority using connections over cheap mobile phones. Even in...
Blog Post
September 11, 2023
It is standard fare for the G20 to issue lofty statements without any real muscle behind them, but the discordance in this year’s declaration is especially grating because explicitly and implicitly, the G20 have heaped exceptionally large burdens on the MDBs all in the context of what the leaders ac...
Blog Post
September 08, 2023
As the G20 India Summit approaches, India is taking a central seat on the global stage. While much attention will focus on India’s positive economic accomplishments, some of the spotlight will inevitably be on the country’s slow advances on women’s economic empowerment. On paper, India’s family-frie...
Blog Post
September 07, 2023
We have reviewed each of the UK’s seven main finance tools—from export finance to capital increases at its private finance arm, British International Investment. Overall, we find that the UK has substantially increased the level of finance it mobilises, from around £3bn in 2018, to £5bn in 2021, and...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...